Issues
-
Cover Image
Cover Image
This image combines in vitro and in silico demonstrations of environmental niches that drive phenotypic segregation in mixed metabolic phenotype spheroids. In vitro: Coculture of low glycolytic MCF7-GFP and high glycolytic MDA-MB-231-RFP as spheroids started with a random mixture of both cells and over time each cell line moved to their favorable habitat, MDA-MB-231 to the edge and MCF7 to the center. In silico: Simulation of a mathematical model of tumor cells with low (green) and high (red) glycolytic phenotypes, subject to a gradient of nutrients similar to a spheroid. The simulation was initialized with equal numbers of both cell types, well-mixed. Over time, the glycolytic phenotypes moved to the edge in the simulation. For details, see article by Ibrahim-Hashim and colleagues on page 2242. - PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkEditorial Board
Cancer Research
Table of Contents
Breaking Advances
Reviews
Perspective
Meeting Report
Regulatory Aspects of Optical Methods and Exogenous Targets for Cancer Detection
Priority Report
Clinical Studies
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer
Circulating Tumor Cells with Aberrant ALK Copy Number Predict Progression-Free Survival during Crizotinib Treatment in ALK-Rearranged Non–Small Cell Lung Cancer Patients
Integrated Systems and Technologies
Defining Cancer Subpopulations by Adaptive Strategies Rather Than Molecular Properties Provides Novel Insights into Intratumoral Evolution
Microenvironment and Immunology
Soluble IL6R Expressed by Myeloid Cells Reduces Tumor-Specific Th1 Differentiation and Drives Tumor Progression
MYC Mediates Large Oncosome-Induced Fibroblast Reprogramming in Prostate Cancer
Molecular and Cellular Pathobiology
NR4A3 Suppresses Lymphomagenesis through Induction of Proapoptotic Genes
Krüppel-like Transcription Factor KLF10 Suppresses TGFβ-Induced Epithelial-to-Mesenchymal Transition via a Negative Feedback Mechanism
Therapeutics, Targets, and Chemical Biology
HuR Small-Molecule Inhibitor Elicits Differential Effects in Adenomatosis Polyposis and Colorectal Carcinogenesis
High-Throughput Genomic Profiling of Adult Solid Tumors Reveals Novel Insights into Cancer Pathogenesis
Targeted Degradation of BET Proteins in Triple-Negative Breast Cancer
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
Energy Balance Modulation Impacts Epigenetic Reprogramming, ERα and ERβ Expression, and Mammary Tumor Development in MMTV-neu Transgenic Mice
Tumor and Stem Cell Biology
The Histone Methyltransferase DOT1L Promotes Neuroblastoma by Regulating Gene Transcription
Letters to the Editor
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.